Recent Finacing
Recent Raise
PlasmaTech develops protein biologic therapies and oncology supportive-care products using Salt Diafiltration (SDF™) and Polymer Hydrogel Technology (PHT™), markets MuGard and ProctiGard, and advances an SDF-derived alpha‑1 protease inhibitor.
This company doesn't have industry or investor information available.
Funding round